Amarin Corp Plc (AMRN)

[JBWIN]

AMRN CEO Karim Mikhail did not set expectations for the PREPARE-IT-1 late-breaking science presentation during the 2Q2021 earnings call. In fact, there was no reference to it.

Here is the only relevant excerpt re Life Cycle Management (LCM):

We plan not to waste any opportunity that will allow us to leverage the investment in our global commercial infrastructure. The first work stream we are prioritizing is our own lifecycle planning for VASCEPA. Icosapent ethyl has proven to be a beneficial molecule in a number of clinical settings. And we are actively evaluating other potential research settings in which to further explore and characterize the drugs activity. And these efforts will align with clinical and commercial needs across individual and global markets for the brand.